179 related articles for article (PubMed ID: 239250)
1. Cardiac adenylate cyclase activity in relation to beta-adrenergic responses.
Wollemann M; Borbola J; Papp J; Szekeres L
J Mol Cell Cardiol; 1975 Jul; 7(7):523-33. PubMed ID: 239250
[No Abstract] [Full Text] [Related]
2. [Hydroxybenzylpindolol--activation mechanism of adenylate cyclase and beta-adrenergic receptor].
Yamamura H
Nihon Rinsho; 1976; 34(3):534-9. PubMed ID: 6811
[No Abstract] [Full Text] [Related]
3. Catecholamine-sensitive adenylate cyclase of human fat cell ghosts: a comparative study using different beta-adrenergic agents.
Kather H; Simon B
Metabolism; 1977 Nov; 26(11):1179-84. PubMed ID: 20550
[TBL] [Abstract][Full Text] [Related]
4. Cardiostimulatory effects of prenalterol, a beta-1 adrenoceptor partial agonist, in vivo and in vitro. Correlation between physiological effects and adenylate cyclase activity.
Hedberg A; Carlsson E; Fellenius E; Lundgren B
Naunyn Schmiedebergs Arch Pharmacol; 1982 Feb; 318(3):185-91. PubMed ID: 6121296
[TBL] [Abstract][Full Text] [Related]
5. Activation of cardiac EP3 receptors by PGE1 reduces beta-adrenergic inotropic effects.
Hohlfeld T; Schrör K
Adv Exp Med Biol; 1997; 433():447-50. PubMed ID: 9561192
[No Abstract] [Full Text] [Related]
6. In kitten ventricular myocardium, the inotropic potency of an agonist is determined by both its intrinsic activity for the adenylyl cyclase and its affinity for the beta-adrenoceptors.
Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 1981 Aug; 317(1):13-8. PubMed ID: 6116196
[No Abstract] [Full Text] [Related]
7. Prenalterol, a non-selective beta-adrenoceptor ligand with absolute beta1-selective partial agonist activity.
Hedberg A; Mattsson H; Carlsson E
J Pharm Pharmacol; 1980 Sep; 32(9):660-1. PubMed ID: 6107374
[No Abstract] [Full Text] [Related]
8. Pharmacological analysis of the cardiac actions of xamoterol, a beta adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: evidence for involvement of adenylate cyclase system in its cardiac stimulant actions.
Hattori Y; Sakuma I; Nakao Y; Kanno M
J Pharmacol Exp Ther; 1987 Sep; 242(3):1077-85. PubMed ID: 2888870
[TBL] [Abstract][Full Text] [Related]
9. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity.
Böhm M; Mittmann C; Schwinger RH; Erdmann E
Am Heart J; 1990 Dec; 120(6 Pt 1):1381-92. PubMed ID: 1978979
[TBL] [Abstract][Full Text] [Related]
10. Structure-binding-activity analysis of beta-adrenergic amines--I. Binding to the beta receptor and activation of adenylate cyclase.
Bilezikian JP; Dornfeld AM; Gammon DE
Biochem Pharmacol; 1978 May; 27(10):1445-54. PubMed ID: 29638
[No Abstract] [Full Text] [Related]
11. Heterogeneity of adenylate cyclase-coupled beta-adrenergic receptors.
Lefkowitz RJ
Biochem Pharmacol; 1975 Mar; 24(5):583-90. PubMed ID: 235928
[No Abstract] [Full Text] [Related]
12. Cholinergic antagonism of beta-adrenergic stimulated action potentials and adenylate cyclase activity in rabbit ventricular cardiomyocytes.
Watson JM; Vogel SM; Cotterell DJ; Dubocovich ML
Eur J Pharmacol; 1988 Oct; 155(1-2):101-8. PubMed ID: 2468508
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Selectivity in beta-adrenergic responses: clinical implications.
Lefkowitz RJ
Circulation; 1974 May; 49(5):783-6. PubMed ID: 4151328
[No Abstract] [Full Text] [Related]
14. Exfoliation of the beta-adrenergic receptor and the regulatory components of adenylate cyclase by cultured rat glioma C6 cells.
Kassis S; Lauter CJ; Stojanov M; Salem N
Biochim Biophys Acta; 1986 May; 886(3):474-82. PubMed ID: 2871868
[TBL] [Abstract][Full Text] [Related]
15. [Cardiac beta receptors--experimental aspects].
Kaumann AJ
Z Kardiol; 1983 Feb; 72(2):63-82. PubMed ID: 6133398
[TBL] [Abstract][Full Text] [Related]
16. The resolution of dopamine and beta 1- and beta 2-adrenergic-sensitive adenylate cyclase activities in homogenates of cat cerebellum, hippocampus and cerebral cortex.
Dolphin A; Hamont M; Bockaert J
Brain Res; 1979 Dec; 179(2):305-17. PubMed ID: 41616
[TBL] [Abstract][Full Text] [Related]
17. Beta adrenergic receptors mediate adenylate cyclase responses in rat cerebral capillaries.
Palmer GC
Neuropharmacology; 1980 Jan; 19(1):17-23. PubMed ID: 6102354
[No Abstract] [Full Text] [Related]
18. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.
Joseph SS; Lynham JA; Molenaar P; Grace AA; Colledge WH; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):496-503. PubMed ID: 14608456
[TBL] [Abstract][Full Text] [Related]
19. Apparent superiority of H2-receptor stimulation and simultaneous beta-blockade over conventional treatment with beta-sympathomimetic drugs in post-acute myocardial infarction: cardiac effects of impromidine--a new specific H2-receptor agonist-in the surviving catecholamine-insensitive myocardium.
Baumann G; Felix SB; Heidecke CD; Riess G; Loher U; Ludwig L; Blömer H
Agents Actions; 1984 Oct; 15(3-4):216-28. PubMed ID: 6151806
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cardiac adenylate cyclase activity in rodent models of obesity.
Strassheim D; Houslay MD; Milligan G
Biochem J; 1992 Apr; 283 ( Pt 1)(Pt 1):203-8. PubMed ID: 1348926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
